AZTA Quote, Financials, Valuation and Earnings

Bruker Corp. has a net margin of 32.45% compared to Azenta, Inc.'s net margin of -6.8%. Azenta, Inc.'s return on equity of 1.44% beat Bruker Corp.'s return on equity of -1.2%.

Azenta, Inc. has a consensus price target of $43.50, signalling upside risk potential of 14.72%. On the other hand Bruker Corp. has an analysts' consensus of $53.14 which suggests that it could fall by -2.42%. Given that Azenta, Inc. has higher upside potential than Bruker Corp., analysts believe Azenta, Inc. is more attractive than Bruker Corp..

Azenta, Inc. has a beta of 1.316, which suggesting that the stock is 31.601% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.854%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.37% to investors and pays a quarterly dividend of $0.05 per share. Azenta, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Azenta, Inc. quarterly revenues are $159.2M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Azenta, Inc.'s net income of $51.7M is higher than Bruker Corp.'s net income of -$58.5M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 2.92x versus 2.40x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience, Inc. has a net margin of 32.45% compared to Azenta, Inc.'s net margin of -5.98%. Azenta, Inc.'s return on equity of 1.44% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.

Azenta, Inc. has a consensus price target of $43.50, signalling upside risk potential of 14.72%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 217.26%. Given that Harvard Bioscience, Inc. has higher upside potential than Azenta, Inc., analysts believe Harvard Bioscience, Inc. is more attractive than Azenta, Inc..

Azenta, Inc. has a beta of 1.316, which suggesting that the stock is 31.601% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.526, suggesting its more volatile than the S&P 500 by 52.562%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta, Inc. pays -- of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend.

Azenta, Inc. quarterly revenues are $159.2M, which are larger than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Azenta, Inc.'s net income of $51.7M is higher than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 2.92x versus 0.32x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kestra Medical Technologies Ltd. has a net margin of 32.45% compared to Azenta, Inc.'s net margin of -145.29%. Azenta, Inc.'s return on equity of 1.44% beat Kestra Medical Technologies Ltd.'s return on equity of -105.99%.

Azenta, Inc. has a consensus price target of $43.50, signalling upside risk potential of 14.72%. On the other hand Kestra Medical Technologies Ltd. has an analysts' consensus of $29.43 which suggests that it could grow by 20.46%. Given that Kestra Medical Technologies Ltd. has higher upside potential than Azenta, Inc., analysts believe Kestra Medical Technologies Ltd. is more attractive than Azenta, Inc..

Azenta, Inc. has a beta of 1.316, which suggesting that the stock is 31.601% more volatile than S&P 500. In comparison Kestra Medical Technologies Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta, Inc. pays -- of its earnings as a dividend. Kestra Medical Technologies Ltd. pays out 1.45% of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Azenta, Inc. quarterly revenues are $159.2M, which are larger than Kestra Medical Technologies Ltd. quarterly revenues of $22.6M. Azenta, Inc.'s net income of $51.7M is higher than Kestra Medical Technologies Ltd.'s net income of -$32.8M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Kestra Medical Technologies Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 2.92x versus 16.89x for Kestra Medical Technologies Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Precipio, Inc. has a net margin of 32.45% compared to Azenta, Inc.'s net margin of -1.17%. Azenta, Inc.'s return on equity of 1.44% beat Precipio, Inc.'s return on equity of -10.15%.

Azenta, Inc. has a consensus price target of $43.50, signalling upside risk potential of 14.72%. On the other hand Precipio, Inc. has an analysts' consensus of -- which suggests that it could fall by -23.29%. Given that Azenta, Inc. has higher upside potential than Precipio, Inc., analysts believe Azenta, Inc. is more attractive than Precipio, Inc..

Azenta, Inc. has a beta of 1.316, which suggesting that the stock is 31.601% more volatile than S&P 500. In comparison Precipio, Inc. has a beta of 1.119, suggesting its more volatile than the S&P 500 by 11.857%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precipio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta, Inc. pays -- of its earnings as a dividend. Precipio, Inc. pays out -- of its earnings as a dividend.

Azenta, Inc. quarterly revenues are $159.2M, which are larger than Precipio, Inc. quarterly revenues of $6.8M. Azenta, Inc.'s net income of $51.7M is higher than Precipio, Inc.'s net income of -$79K. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Precipio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 2.92x versus 1.69x for Precipio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.